scholarly journals “Post-COVID syndrome”: The focus is on musculoskeletal pain

2021 ◽  
Vol 59 (3) ◽  
pp. 255-262
Author(s):  
A. E. Karateev ◽  
V. N. Amirdzhanova ◽  
E. L. Nasonov ◽  
A. M. Lila ◽  
L. I. Alekseeva ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Chronic Fatigue ◽  
Organ Damage ◽  
Modern Medicine ◽  
Multiple Organ ◽  
Functional Disorders ◽  
Fatigue Syndrome ◽  
Urgent Task ◽  
Long Time ◽  
Autoimmune Processes

Combating the consequences of COVID-19, a disease caused by the new coronavirus infection SARS-CoV-2, is a serious and very urgent task facing modern medicine. COVID-19 often has a severe course and is accompanied by multiple organ damage, systemic immune inflammation, coagulopathy, neuroendocrine and metabolic disorders. Even with a relatively favorable course, the consequences of SARS-CoV-2 infection can be degenerative changes in many organs (pulmonary fibrosis, cardiosclerosis), various functional and psychoemotional disorders. As a result, in 10–50% of patients, various unpleasant symptoms persist for a long time after the acute manifestations of COVID-19 subside and the virus is eliminated. This pathology is referred to as “post-COVID syndrome” (PCS). The main elements of PCS are chronic pain, fatigue, and psychoemotional problems. Functional disorders, autoimmune processes, and severe psychological distress after COVID-19 can cause the development and exacerbation of diseases characterized by chronic pain and fatigue, such as fibromyalgia and chronic fatigue syndrome. Therapy and prevention of PCS include correction of functional disorders, pain control, and consistent physical, psychological, and social rehabilitation.

scholarly journals Exercise Performance and Chronic Pain in Chronic Fatigue Syndrome: The Role of Pain Catastrophizing

Pain Medicine ◽  
2008 ◽  
Vol 9 (8) ◽  
pp. 1164-1172 ◽  
Author(s):  
Jo Nijs ◽  
Karen Van de Putte ◽  
Fred Louckx ◽  
Steven Truijen ◽  
Kenny De Meirleir
Keyword(s):  
Chronic Pain ◽  
Chronic Fatigue Syndrome ◽  
Exercise Performance ◽  
Pain Catastrophizing ◽  
Chronic Fatigue ◽  
Fatigue Syndrome

scholarly journals Chronic Pain and Fatigue: Associations with Religion and Spirituality

2008 ◽  
Vol 13 (5) ◽  
pp. 383-388 ◽  
Author(s):  
Marilyn Baetz ◽  
Rudy Bowen
Keyword(s):  
Chronic Pain ◽  
Well Being ◽  
Chronic Fatigue ◽  
Canadian Community Health Survey ◽  
Health Care Use ◽  
Spiritual Support ◽  
Religion And Spirituality ◽  
Psychological Well Being ◽  
Migraine Headaches ◽  
Fatigue Syndrome

BACKGROUND: Conditions with chronic, non-life-threatening pain and fatigue remain a challenge to treat, and are associated with high health care use. Understanding psychological and psychosocial contributing and coping factors, and working with patients to modify them, is one goal of management. An individual’s spirituality and/or religion may be one such factor that can influence the experience of chronic pain or fatigue.METHODS: The Canadian Community Health Survey (2002) obtained data from 37,000 individuals 15 years of age or older. From these data, four conditions with chronic pain and fatigue were analyzed together – fibromyalgia, back pain, migraine headaches and chronic fatigue syndrome. Additional data from the survey were used to determine how religion and spirituality affect psychological well-being, as well as the use of various coping methods.RESULTS: Religious persons were less likely to have chronic pain and fatigue, while those who were spiritual but not affiliated with regular worship attendance were more likely to have those conditions. Individuals with chronic pain and fatigue were more likely to use prayer and seek spiritual support as a coping method than the general population. Furthermore, chronic pain and fatigue sufferers who were both religious and spiritual were more likely to have better psychological well-being and use positive coping strategies.INTERPRETATION: Consideration of an individual’s spirituality and/or religion, and how it may be used in coping may be an additional component to the overall management of chronic pain and fatigue.

scholarly journals THE MAIN CLINICAL SYNDROMES ASSOCIATED WITH ACTIVE CRONIC ATIPICAL EPSTEINE-BARR VIRUS INFECTION: CREATED ALGORITHM OF CLINICAL AND LABORATORY DIAGNOSTIC

2019 ◽  
Vol 23 (1) ◽  
pp. 70-78
Author(s):  
I. V. Nesterova ◽  
E. O. Khalturina
Keyword(s):  
Clinical Symptoms ◽  
Chronic Fatigue ◽  
Modern Medicine ◽  
Steady Increase ◽  
Laboratory Diagnostics ◽  
Antiviral Defense ◽  
Defense System ◽  
Barr Virus ◽  
Fatigue Syndrome ◽  
Clinical Syndromes

The annual steady increase of the herpesviral infections number in the human population is one of the most important interdisciplinary problems of modern medicine. Clinicians and laboratory diagnostics physicians face difficulties in clinical symptoms assessing, inadequate laboratory diagnostics and difficulties in interpretation of the obtained results. This is connected with a low awareness of atypical chronic active infection symptoms caused in particular by the Epstein-Barr virus (EBV), of the ability to fully diagnose, and of serious consequencescaused by prolonged activity of herpesviruses in the human body. Studies were carried out to determinethe functioning features of the antiviral defense system, as well as defects and disorders in the interferon system in patients suffering from various mono-, mixed herpesvirus infections and bacterial co-infections. The main clinical syndromes associated with these herpetic infections, as well as prevailing nosological forms of concomitant diseases, have been identified. Among the group of patients suffering from mono-herpesvirus infections, the leading position takes the allergic syndrome (55%), while the syndrome of chronic fatigue syndrome (85%) and the infectious syndrome (68%) prevail in the incidence of patients with mixed herpesvirus infections. Extended testing of the antiviral protection main mechanisms state made it possible to identify the most frequent defects in the functioning of antiviral immunity: disturbances in induced production of IFNα and IFNγ, deficiency of cytotoxic T lymphocytes, deficiency of natural killer cells, including EKT, and / or inadequate absence of their activation, neutropenia. The revealed clinical syndromes and functioning features of the antiviral defense system will allow us to further develop the concept of complex, individualized, etio- and immunopathogenetic therapy.

scholarly journals POS0061-PARE HOW DO THE COMPLICATIONS OF SPONDYLOARTHRITIS (SPA*) IMPACT THE QUALITY OF LIFE (QOL) OF PATIENTS LIVING WITH SPA?

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 237.1-237
Author(s):  
S. Patenaude ◽  
W. Gerhart
Keyword(s):  
Chronic Pain ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Delayed Diagnosis ◽  
Prescription Medication ◽  
Chronic Fatigue ◽  
Irreversible Damage ◽  
Fatigue Syndrome ◽  
Sleeping Pills ◽  
Disc Herniations

Background:SpA describes a group of chronic inflammatory arthritic diseases with common features, including inflammation of the spine, eyes, skin and gastrointestinal tract. These conditions can be painful and debilitating for many. Delayed diagnosis and treatment can lead to irreversible damage to the spine and other joints. Diagnosis of these conditions can take, on average, 7 years or more. We don’t know what causes SpA and there is no cure. The onset of symptoms can be in early childhood and expands throughout one’s lifespan. It affects children, women and men worldwide.Objectives:To understand how the complications of living with SpA impacts QOL as well as what is important to patients in order to help the CSA** prioritize advocacy focus and resource development.Methods:The CSA surveyed the community virtually from 11/19/19 to 01/21/20. The results of 838 respondents were analyzed after the survey closed. 466 participants responded to the questions regarding complications.Results:In total, participants had an average of 3.3 complications. Those living with ankylosing spondylitis experienced an average of 3.5 while those with psoriatic arthritis reported an average of 3.9.Sleep issues (65%), chronic pain (63%), and combined depression and anxiety (56%) were the most prevalent conditions reported among participants. In addition, 23% said they live with inflammatory bowel disease. Other complications include uveitis, weight issues, migraine, vertebral disc herniations and hypertension.Those who reported weight issues (over 44%) consequently had increased anxiety, depression and chronic pain compared to those without weight issues.Over 65% reported experiencing sleep issues. Many (26%) said that nothing helps with their sleep. Others used cannabis (24%), prescribed sleeping pills (20%) and exercise (19%) to cope.36% of participants said that they suffer from chronic fatigue syndrome. When asked how they manage their fatigue, the most common answer was exercise. Most participants said they have yet to find something that helps them efficiently manage their fatigue.Over 400 people said they suffer from either depression or anxiety, or both. When asked how they cope with this, 40% said talking to loved ones. Exercise to cope was reported by 32% and 31% take prescription medication. Those who suffer from Psoriasis experienced a higher prevalence of anxiety and depression.Conclusion:Overall, the presence of complications is an additional stressor to SpA patients. Many pointed out that the complications are sometimes more burdensome than the actual SpA condition and some patients even prioritize the management of the complications over the actual SpA condition. These complications can lead to increased trips to the physician resulting in more healthcare interventions and medications, causing frustration to patients.Only 59% of respondents mentioned that their rheumatologist regularly asks them about additional complications such as depression, fatigue and gut issues. Many felt that their rheumatologist seems to be more concerned with pain management and continuing function and do not necessarily address other health concerns and complications, particularly mental health. Although these are often overlooked, it is clear that complications have a significant impact on patient health and overall QOL.The CSA is committed to developing programs and resources to help patients manage all the complications commonly experienced to improve health outcomes and overall QOL.It doesn’t have to be visible to be real. Together we are stronger!References:[1]SpA conditions include: Ankylosing Spondylitis, Psoriatic Arthritis, non-radial SpA, Axial SpA, Peripheral Spondyloarthritis, Enteropathic Arthritis, Reactive Arthritis and Juvenile Onset Arthritis[2]The Canadian Spondylitis Association (CSA) is a national non-profit patient association supporting and advocating for those living with SpA.Disclosure of Interests:None declared.

scholarly journals Features of Reparative Histogenesis in Bioplastic Material Application

2020 ◽  
Vol 9 (1) ◽  
pp. 86-93
Author(s):  
N. N. Shevlyuk ◽  
I. Z. Gatiatullin ◽  
A. A. Stadnikov
Keyword(s):  
Connective Tissue ◽  
Degradation Products ◽  
Three Dimensional ◽  
Organ Damage ◽  
Modern Medicine ◽  
The Body ◽  
Biologically Active ◽  
Pharmacological Agents ◽  
Body Tissues ◽  
Urgent Task

In modern medicine, various biocompatible materials (based on biodegradable natural biopolymers – collagen, hyaluronic acid, chitin, chitosan, etc.) are widely used, primarily for the purposes of reconstructive and plastic surgery. The development of these materials and their introduction into clinical practice is an extremely urgent task of regenerative biology and medicine. One of the most important properties of bioplastic materials is their ability to undergo biodegradation and gradually be replaced by the recipient's proper tissues. In this case, the intermediate and final metabolic products of these materials should be included in the natural biochemical cycles of the body without their systemic and local accumulation, and degradation products should lack the toxicity effect. Bioplastic materials can also serve as carriers of biologically active substances, for example, growth factors and morphogenetic proteins, antibacterial substances, as well as pharmacological agents that affect the rate of regeneration. The designed three-dimensional porous structure of new materials, morphologically similar to the structure of body tissues, allows them to ensure the migration of fibroblastic cells, the growth of blood vessels in the area occupied by this material, that is, they can serve as a skeleton (matrix), a basis for histio- and organotypic regenerates developing in various organs. Many bioplastic materials have the ability to enhance angiogenesis, and are also able to activate proliferation and cytodifferentiation of epithelial cells and fibroblast differentiation cells of the connective tissue, which leads to the formation of young connective tissue in the transplant zone and epithelization of organ damage. Thus, biocompatible and biodegradable polymers are able to stimulate reparative histogenesis, providing optimal conditions for the formation of histio- and organotypic regenerates of various tissues and organs.

scholarly journals Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis

2021 ◽  
Vol 15 ◽  
Author(s):  
Adonis Sfera ◽  
Carolina Osorio ◽  
Carlos M. Zapata Martín del Campo ◽  
Shaniah Pereida ◽  
Steve Maurer ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Viral Infections ◽  
Life Quality ◽  
Chronic Fatigue ◽  
Myalgic Encephalomyelitis ◽  
Unknown Etiology ◽  
Host Proteins ◽  
Fatigue Syndrome ◽  
Long Time ◽  
Sleep Abnormalities

Myalgic encephalomyelitis/chronic fatigue syndrome is a serious illness of unknown etiology, characterized by debilitating exhaustion, memory impairment, pain and sleep abnormalities. Viral infections are believed to initiate the pathogenesis of this syndrome although the definite proof remains elusive. With the unfolding of COVID-19 pandemic, the interest in this condition has resurfaced as excessive tiredness, a major complaint of patients infected with the SARS-CoV-2 virus, often lingers for a long time, resulting in disability, and poor life quality. In a previous article, we hypothesized that COVID-19-upregulated angiotensin II triggered premature endothelial cell senescence, disrupting the intestinal and blood brain barriers. Here, we hypothesize further that post-viral sequelae, including myalgic encephalomyelitis/chronic fatigue syndrome, are promoted by the gut microbes or toxin translocation from the gastrointestinal tract into other tissues, including the brain. This model is supported by the SARS-CoV-2 interaction with host proteins and bacterial lipopolysaccharide. Conversely, targeting microbial translocation and cellular senescence may ameliorate the symptoms of this disabling illness.

Chronic Fatigue Syndrome: From Chronic Fatigue to More Specific Syndromes

2018 ◽  
Vol 80 (1-2) ◽  
pp. 73-77 ◽  
Author(s):  
Svetlana Blitshteyn ◽  
Pradeep Chopra
Keyword(s):  
Chronic Pain ◽  
Chronic Fatigue Syndrome ◽  
Symptomatic Treatment ◽  
Chronic Fatigue ◽  
Fatigue Syndrome ◽  
Immune Mediated ◽  
Therapeutic Algorithm ◽  
Chronic Disorders ◽  
Clinical Paradigm ◽  
Pathophysiologic Mechanisms

In the last decade, a group of chronic disorders associated with fatigue (CDAF) emerged as the leading cause of chronic fatigue, chronic pain, and functional impairment, all of which have been often labeled in clinical practice as chronic fatigue syndrome (CFS) or fibromyalgia. While these chronic disorders arise from various pathophysiologic mechanisms, a shared autoimmune or immune-mediated etiology could shift the focus from symptomatic treatment of fatigue and pain to targeted immunomodulatory and biological therapy. A clinical paradigm shift is necessary to reevaluate CFS and fibromyalgia diagnoses and its relationship to the CDAF entities, which would ultimately lead to a change in diagnostic and therapeutic algorithm for patients with chronic fatigue and chronic pain. Rather than uniformly apply the diagnoses of CFS or fibromyalgia to any patient presenting with unexplained chronic fatigue or chronic pain, it may be more beneficial and therapeutically effective to stratify these patients into more specific diagnoses in the CDAF group.

The economic burden of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): an initial summary of the existing evidence and recommendations for further research

2017 ◽  
Vol 5 (3) ◽  
pp. 413 ◽  
Author(s):  
Elenka Brenna ◽  
Lara Gitto
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Literature Review ◽  
Economic Burden ◽  
Indirect Costs ◽  
Chronic Fatigue ◽  
Modern Medicine ◽  
Myalgic Encephalomyelitis ◽  
Policy Implications ◽  
Fatigue Syndrome ◽  
The Many

Background: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) describes a condition of chronic weakness that cannot be alleviated by rest and which is associated with lower quality of life and higher healthcare utilization. In Western countries, its prevalence ranges from 0.2% to 1%. Despite the many efforts carried out during recent decades to investigate the nature of this syndrome, there are still uncertainties and controversies with respect to its definition, diagnosis and what constitutes optimal treatment. Some authors suggest that there may be a significant percentage of patients that are not yet diagnosed with this illness, due to the difficulty in identifying the symptoms. Thus, the economic burden of the disease remains unclear, although it is well recognized that the costs associated with CFS are mainly related to productivity loss.Methods: A literature review was conducted to investigate this topic, by considering, with a chronological perspective, the most relevant contributions focussed on the economic costs and consequences of CFS/ME. Results: The literature review describes how the economic burden of CFS has been increasingly considered over recent decades and addresses the aspects of CFS that deserve more attention as this field of study moves forward.Conclusion: The economic burden of CFS has not been well studied, but recent research demonstrates an increasing interest in the direct and indirect costs of CFS on individuals and Society. The need to establish an optimal, person-centered approach to the diagnosis, management and follow-up of CFS, is an imperative for modern medicine, given the relationship between the nature of clinical practice and the costs incurred by CFS. Further research is required to explore this relationship and to define its policy implications.

Sign in / Sign up

Export Citation Format

Share Document